We are getting extremely excited about our upcoming presence at AACR22! Biognosys will be presenting a talk and five scientific posters demonstrating the technological advances and utility of our TrueDiscovery™ and TrueTarget™ proteomics platforms in oncology R&D and clinical settings. Visit us at booth 855 in the exhibition hall.

Did you miss the webinar "3D proteome snapshots enable high-resolution functional proteomics screens" with our outstanding speaker Prof. Paola Picotti, from ETH, on Nature Research Custom Media? Forgot about the webinar “Immunotherapy meets proteomics: A winning combination for clinical trial success and personalized treatment?” in collaboration with PICI on Science? No problem!

In this first Biognosys Spotlight episode, Yuehan, our Scientific Alliances Director, will walk through the Biognosys research services to deliver you deep proteomics insights for drug discovery and development. Jakob, our Head of Discovery Proteomics, will show you where the magic happens: our state-of-the-art lab operations and data analysis.

With no cures currently available for neurodegenerative diseases, we urgently need better information about developing conditions like Alzheimer's and Parkinson's. With our proteomics platforms, we can open a window into the brain, revealing new clues in the search for more effective therapies.

250,000 peptides. 13,000 proteins. 20 different post-translational modifications. It all adds up to a big breakthrough in our tissue proteomics capability – the market's deepest, single-shot proteomics service. We continue to refine and optimize our technology and analytical tools to dive deeper into the proteomes and bring you transformative insights to reach true biology.